Psyence BioMed has completed its investment in PsyLabs following regulatory readiness and manufacturing milestones, supporting PsyLabs’ intended supply of pharmaceutical-grade ibogaine for a planned U.S. development program.
Psyence BioMed’s Texas subsidiary, TIRC, has partnered with Benuvia to establish a pathway for US ibogaine manufacturing. The agreement aims to support pharmaceutical-grade production in Texas for future regulated research and clinical development, subject to applicable DEA quotas and regulatory authorisations.
syence BioMed’s Texas subsidiary has signed a binding term sheet with PsyLabs covering exclusive U.S. ibogaine development, supply and distribution rights. The parties aim to conclude a definitive agreement by November 30, 2026.
Psyence BioMed has agreed to invest up to US$5 million in PsyLabs and pursue a share exchange to support manufacturing and development for its planned US ibogaine program. A potential Texas clinical trial remains under evaluation.
Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity
Psyence BioMed welcomes renewed federal support for ibogaine development and outlines how its pharmaceutical manufacturing platform can contribute to responsible clinical research in the United States.
Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Psyence BioMed has begun its NPX-5 psilocybin trial, dosing the first patient in a Phase IIb study targeting adjustment disorder in palliative care.
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
